Dr. Valent on Dose-Adjusted Carfilzomib in Myeloma

Jason Valent, MD
Published: Monday, Nov 05, 2018



Jason Valent, MD, an oncologist at Cleveland Clinic, discusses the recent FDA approval to expand prescribing information to include a once-weekly dosing option for carfilzomib (Kyprolis) to use in combination with dexamethasone for the treatment of patients with relapsed/refractory myeloma.

The FDA based their decision on results from the phase III ARROW study, which demonstrated that carfilzomib administered once weekly at 70 mg/m2 with dexamethasone resulted in a prolonged progression-free survival (PFS) compared with the standard twice-a-week treatment. Median PFS was 11.2 months with the once-weekly schedule versus 7.6 months with the twice-weekly regimen.

The biggest advantage of this new dosing regimen is that it is more convenient for patients, Valent says. Instead of going to the clinic twice-a-week on consecutive days, patients now only have to go once. Valent adds that the new regimen may also reduce the toxicities associated with carfilzomib, despite the higher dose.
SELECTED
LANGUAGE


Jason Valent, MD, an oncologist at Cleveland Clinic, discusses the recent FDA approval to expand prescribing information to include a once-weekly dosing option for carfilzomib (Kyprolis) to use in combination with dexamethasone for the treatment of patients with relapsed/refractory myeloma.

The FDA based their decision on results from the phase III ARROW study, which demonstrated that carfilzomib administered once weekly at 70 mg/m2 with dexamethasone resulted in a prolonged progression-free survival (PFS) compared with the standard twice-a-week treatment. Median PFS was 11.2 months with the once-weekly schedule versus 7.6 months with the twice-weekly regimen.

The biggest advantage of this new dosing regimen is that it is more convenient for patients, Valent says. Instead of going to the clinic twice-a-week on consecutive days, patients now only have to go once. Valent adds that the new regimen may also reduce the toxicities associated with carfilzomib, despite the higher dose.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Medical Crossfire®: Personalizing Care for Multiple Myeloma Patients: Current and Future Sequencing StrategiesMay 31, 20191.5
Publication Bottom Border
Border Publication
x